Items tagged with Access
MSF video: Push, pull and pool: accelerating innovation and access for new treatment regimens for TB (post)
Current modes of research and development have failed to deliver new and better TB regimens to patients; as such, MSF and others are proposing a new way to conduct TB regimen research, in the form of the 3P project. The ‘3P Project’ aims to rapidly deliver affordable, effective new regimens for TB through an open collaborative approach to conducting drug development, using novel approaches to financing and coordinating R&D.
The Medicines Patent Pool statement on potential extension of its mandate to hepatitis C and tuberculosis (post)
The MPP acknowledges the recent response and input from various civil society organisations and treatment groups on the Foundation’s ongoing assessments to determine the feasibility of extending its mandate to include medicines for hepatitis C (HCV) and tuberculosis (TB).
Support for extension of transitional period and waivers of least developed countries on TRIPS Agreement (post)
The Communities living with HIV and Tuberculosis and affected by malaria Delegation (Communities Delegation) on the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) expresses its full support for the request submitted by Bangladesh at the WTO TRIPS Council in October 2014, on behalf of the Least Developed Countries (LDCs), for an extension of the transitional period under Article 66.1 of the TRIPS Agreement with respect to pharmaceutical products and for waivers from the obligations of Articles 70.8 and 70.9 of the TRIPS Agreement (IP/C/W/605).
MSF and DNDi join call for a biomedical research and development fund and mechanism to meet pressing global health needs (post)
A group of renowned global health experts*, including from Médecins Sans Frontières (MSF) and the Drugs for Neglected Diseases initiative (DNDi), are calling for the creation of a global health research and development (R&D) fund and mechanism to address deadly gaps in innovation for emerging infectious diseases such as Ebola, anti-microbial resistance, and a host of other diseases that have been neglected by the pharmaceutical market. The call comes at a time when these and other public health challenges are high on political agendas in the lead up to World Health Assembly next week and the G7 Summit in June.
amfAR: Issue brief: Trans-Pacific Partnership: Curbing access to medicines now and in the future (May 2015) (post)
The Trans-Pacific Partnership (TPP) is currently being negotiated among 12 Pacific Rim countries: Australia, Brunei, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore, the United States, and Vietnam. If passed, it will become the largest U.S. free trade agreement (FTA) in history. It is anticipated that the agreement will expand existing intellectual property (IP) protections on pharmaceutical products, which will ultimately impede access to affordable generic medicines for diseases such as HIV/AIDS, cancer, tuberculosis, and hepatitis C.
MSF responds to publication of new edition of WHO Model List of Essential Medicines (post)
WHO announcement: WHO moves to improve access to lifesaving medicines for hepatitis C, drug-resistant TB and cancers
SA hosts world’s first study into better XDR-TB treatment (post)
South African scientists are spearheading the world’s first trial into shorter and better treatment for tuberculosis (XDR-TB), which kills about half of all those diagnosed with the condition in South Africa.
Workshop on use of bedaquiline to treat extensively drug-resistant tuberculosis (XDR-TB) in Belarus (post)
The National Tuberculosis Programme (NTP) in Belarus, in collaboration with WHO and with the support of the United Nations Development Programme; the Global Fund to Fight AIDS, TB and Malaria (the Global Fund); and Médecins Sans Frontières, organized a workshop on "The use of bedaquiline to treat XDR-TB" on 7 May 2015 at the Republican Scientific and Practical Centre for Pulmonology and Tuberculosis in Minsk, Belarus. The training was conducted by WHO and national experts from NTP and the National Pharmacovigilance Centre and was attended by 28 participants.
Two UN agencies come out in support of extension of TRIPS LDC waiver (post)
The United Nations Development Programme and the Joint UN Programme on HIV/AIDS have issued a joint statement supporting a request by least-developed countries to extend a waiver allowing them to abstain from enforcing patents on pharmaceutical products.
WHO advances R&D financing effort; Global R&D Observatory to launch in January (post)
World Health Organization members in committee this week took note of a report by the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG), which was set up to find ways to fund research on diseases afflicting poor populations which have little market incentive for the private sector. The report included a proposal for a voluntary pooled fund that would focus on the development of effective and affordable health technologies for such neglected diseases.
Page 12 of 83 · Total posts: 0
←First 11 12 13 Last→